XML 73 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Licenses and collaborative arrangement (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 13, 2021
$ / shares
shares
Jan. 31, 2021
USD ($)
Dec. 31, 2020
$ / shares
Jun. 30, 2019
Milestone
Dec. 31, 2017
Investors
Mar. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Milestone
programs
Molecules
$ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Common stock par value | $ / shares     $ 0.00006       $ 0.00006
Issuance of ordinary shares in connection with collaboration and license arrangement           $ 62,250  
Number of molecules | Molecules             2
Number of programs | programs             4
Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Future milestone payments to be made upon achievement             $ 4,541,502
Five Prime              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
License agreement date         2017-12    
Payment of upfront fees             5,000
Number of milestone payments | Investors         1    
Milestone payments             2,000
Five Prime | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Additional milestone payments             37,000
Deciphera Pharmaceuticals LLC              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
License agreement date       2019-06      
Payment of upfront fees             20,000
Milestone payment accrued           $ 12,000  
Number of milestone payments | Milestone       3      
Deciphera Pharmaceuticals LLC | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Additional milestone payments             173,000
Argenx BV              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
License agreement date   2021-01          
Development cost-sharing payment             75,000
Issuance of ordinary shares in connection with collaboration and license arrangement, Shares | shares 568,182            
Common stock par value | $ / shares $ 0.00006            
Issuance of ordinary shares in connection with collaboration and license arrangement             62,250
Future cash payment             25,000
GSK              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Payment of upfront fees             15,000
Milestone payment accrued             $ 3,500
Number of milestone payments Accrued | Milestone             1
Number of milestone payments | Milestone             1,000,000
Milestone payments             $ 1,000
Additional milestone payments             36,000,000
ZLAB Turning Point Therapeutics Inc              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment accrued             $ 3,000
Number of milestone payments Accrued | Milestone             2
Number of milestone payments | Milestone             1
Milestone payments             $ 2,000
Mirati Therapeutics Inc              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Payment of upfront fees for license agreement, accrued             65,000
Future milestone payments to be made upon achievement             $ 273,000
Mirati Therapeutics Inc | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Percentage of tiered royalties on annual net sales             20.00%
Mirati Therapeutics Inc | Minimum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Percentage of tiered royalties on annual net sales             0.00%
MacroGenics              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Payment of upfront fees             $ 25,000
Payment of upfront fees for license agreement, accrued             $ 25,000
Number of milestone payments | Milestone             2
Milestone payments             $ 4,000
Additional milestone payments             136,000
Future milestone payments to be made upon achievement             1,386,000
MacroGenics | Collaboration and License Agreement [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Equity Method Investments             $ 30,000
Issue price per share | $ / shares             $ 31.30
Turning Point Therapeutics Inc              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
License agreement date   2021-01         2020-07
Payment of upfront fees   $ 25,000         $ 25,000
Turning Point Therapeutics Inc | Potential Development Regulatory and Sales Based Milestone              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Additional milestone payments   $ 336,000          
Future milestone payments to be made upon achievement             146,000
Cullinan Pearl Corp              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
License agreement date     2020-12        
Payment of upfront fees             20,000
Cullinan Pearl Corp | Potential Development Regulatory and Sales Based Milestone              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Future milestone payments to be made upon achievement             211,000
Takeda Pharmaceutical Company Limited              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
License agreement date     2020-12        
Payment of upfront fees             6,000
Takeda Pharmaceutical Company Limited | Potential Development Regulatory and Sales Based Milestone              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Future milestone payments to be made upon achievement             $ 481,500